Takeda Pharmaceutical Free Cash Flow (FCF) History (TAK)

Takeda Pharmaceutical reported ¥626.77B in free cash flow for fiscal 2026, a decrease of 26.81% from the previous fiscal year, with a free cash flow margin of 13.91%.

View full Takeda Pharmaceutical company overview

Takeda Pharmaceutical free cash flow by year

Takeda Pharmaceutical annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20262026-03-31¥626.77B−¥229.62B−26.81%+13.91%
20252025-03-31¥856.39B¥315.46B+58.32%+18.69%
20242024-03-31¥540.92B−¥295.57B−35.33%+12.69%
20232023-03-31¥836.50B−¥163.35B−16.34%+20.77%
20222022-03-31¥999.85B¥100.13B+11.13%+28.01%
20212021-03-31¥899.73B¥357.06B+65.80%+28.14%
20202020-03-31¥542.67B¥291.87B+116.37%+16.49%
20192019-03-31¥250.80B−¥60.05B−19.32%+11.96%
20182018-03-31¥310.85B¥111.15B+55.66%+17.56%
20172017-03-31¥199.70B——+11.53%

Takeda Pharmaceutical free cash flow growth trends

Over the last five reported fiscal years, free cash flow declined from ¥899.73B to ¥626.77B, a compound annual decline of 6.97%. Takeda Pharmaceutical's latest reported quarter, Q4 2026, generated ¥10.13B in free cash flow.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Takeda Pharmaceutical source filings ↗

Community posts

It’s quiet here.

No posts about TAK yet. Start the conversation.

Write the first post